From Bench to Bedside

TF: From Bench to Bedside

Date:
13 October 2015 15:00 hrs. - 18:00 hrs.
Location:
Figdor Lecture Theatre, 8th floor RIMLS Building, Geert Grooteplein 26-28, route 289
Title:
RIMLS Technical Forum "From Bench to Bedside" for PhD students
Host(s):

The organising PhD students are:

  • Florian Wimmers
  • Galuh Astuti
  • Florentien in ’t Hout
  • Claire van Houdt
13-10-2015 15:00:0013-10-2015 18:00:00Europe/AmsterdamRIMLS Technical Forum "From Bench to Bedside" for PhD students Figdor Lecture Theatre, 8th floor RIMLS Building, Geert Grooteplein 26-28, route 289Rimlsrimls@radboudumc.nl

Remarks / more information:

 

 

Programme and registration: 

15.00 - 15.05

Introduction to the Technical Forum, announcement of speakers, program overview
Technical forum team, RIMLS, RadboudUMC, Nijmegen

15.05 - 15.30

Introduction to Gene therapy and research techniques, Transcriptional regulated (trans)gene expression for tailor-made gene therapy in rheumatoid arthritis
Dr. Fons van de Loo, Department of Rheumatology, RadboudUMC, Nijmegen
Dr. Fons van de Loo is program leader of Gene Therapy research at the Department of Rheumatology Research and Advanced Therapeutics since 1998. His research interest include inflammation and cell biology, with a special focus on cytokine signaling and development of treatment for rheumatoid arthritis using gene therapeutic approaches. In 2003 he became a VIDI laureate on the topic of transcriptional regulated (trans)gene expression for tailor-made gene therapy in rheumatoid arthritis. His research group is participating in ‘Be The Cure’ collaborative network, a pan-European research initiative funded by IMI which aims to develop new therapies against rheumatoid arthritis.

15.35 - 16.00

Ethical and scientific issues around the development and use of gene therapy
Dr. Kaate Vanmolkot, Centrale Commissie Mensgebonden Onderzoek, Den Haag
The Central Committee on Research Involving Human Subjects (CCMO), as executor of the Medical Research Involving Human Subjects Act (WMO), has a diverse range of tasks. One of these tasks is the review of medical research. Research that falls under the WMO must be reviewed on its medical/scientific and ethical aspects. The reviewing task of the CCMO is limited to specific fields of research, including cell therapy, gene therapy, medicinal products with genetically modified organisms, RNA interference, antisense oligonucleotides, unauthorised vaccines and non-therapeutic interventional research with minors and incapacitated adults.
Dr. Vanmolkot holds a M.Sc. in Biology (Radboud University Nijmegen) and a PhD from Leiden University. Her PhD was followed by a postdoc position, both performed at the Center for Human and Clinical Genetics (LUMC). She is working as a scientific staff member at the secretariat of the CCMO since 2008. She is the contact person for gene therapy related issues and participates in the Gene Therapy Office on behalf of the CCMO.

16.05 - 16.15

Break

16.15 - 16.45

Bringing gene therapy from bench to bedside
Dr. Hans Preusting, CBO, UniQure, Amsterdam
UniQure is an Amsterdam-based biotech company, developing gene therapeutic approaches to treat hereditary or acquired diseases via adeno-associated virus (AAV)-based gene therapies and developed the, so far, only gene therapy product to receive regulatory approval in the European Union.
Dr. Preusting joined uniQure’s predecessor company AMT in August 2006 and is responsible for Business Development. He holds a PhD in Biochemistry and an MBA from Rotterdam School of Management. He has 20 years of experience in product development and manufacturing using fermentation and cell culture techniques. Prior to UniQure, he was at Solvay Pharmaceuticals, DSM and Gist-brocades. Hans Preusting holds two patents and has published over 20 scientific articles. (www.uniqure.com)

16.45 - 17.00 Open discussion round
17.00 - 18.00 Drinks

   

Registration






<< back to all events